Costello Asset Management INC Sells 13,176 Shares of Novo Nordisk A/S (NYSE:NVO)

Costello Asset Management INC decreased its position in shares of Novo Nordisk A/S (NYSE:NVO) by 44.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 16,504 shares of the company’s stock after selling 13,176 shares during the quarter. Costello Asset Management INC’s holdings in Novo Nordisk A/S were worth $1,420,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of NVO. AQR Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 110.5% during the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock worth $2,450,000 after acquiring an additional 9,012 shares in the last quarter. Strategic Investment Solutions Inc. IL bought a new stake in Novo Nordisk A/S during the second quarter worth $25,000. Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in shares of Novo Nordisk A/S by 45.8% in the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 23,664 shares of the company’s stock valued at $3,378,000 after purchasing an additional 7,430 shares in the last quarter. Centaurus Financial Inc. increased its stake in shares of Novo Nordisk A/S by 98.5% in the 2nd quarter. Centaurus Financial Inc. now owns 7,175 shares of the company’s stock valued at $1,024,000 after purchasing an additional 3,560 shares during the last quarter. Finally, Capital Market Strategies LLC raised its holdings in shares of Novo Nordisk A/S by 1.5% during the 3rd quarter. Capital Market Strategies LLC now owns 9,894 shares of the company’s stock worth $1,178,000 after buying an additional 150 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently weighed in on NVO shares. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, StockNews.com cut Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Trading Down 1.2 %

NVO opened at $84.36 on Friday. The company’s 50 day moving average price is $93.56 and its two-hundred day moving average price is $113.22. The firm has a market capitalization of $378.56 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 0.92 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.